WARRINGTON, PA — Windtree Therapeutics, Inc. (OTC: WINT) said it may receive substantial milestone payments after its licensing partner initiated renewed development activity on the company’s acute pulmonary therapies for premature infants, potentially unlocking nearly $79 million tied to the deal.
The update relates to an amended and restated global license agreement executed in August 2022, which covers Windtree’s suite of surfactant-based treatments — including SURFAXIN, lyophilized lucinactant and AEROSURF, a drug–device combination therapy designed to deliver surfactant without the need for invasive intubation. The franchise is intended to treat respiratory distress syndrome, a life-threatening condition that occurs when preterm infants are born without sufficient natural lung surfactant.
Under the agreement, Windtree’s partner is responsible for all development and commercialization costs. The contract includes up to $78.9 million in development, regulatory and commercial milestone payments, as well as low double-digit royalties if the therapies reach the market.
Windtree said it expects to provide additional clarity on potential milestone timing as its partner progresses development plans.
“Windtree has been informed by its licensing partner about its acute pulmonary treatment development plan and we are supportive for these activities,” said CEO Jed Latkin. He noted that RDS remains a serious global condition with an urgent need for innovation, adding that any future milestone or royalty payments would be non-dilutive and could help support the company’s broader corporate strategy.
Respiratory distress syndrome disproportionately affects the earliest preterm infants, often requiring immediate surfactant therapy to sustain life. Windtree’s licensed technologies aim to expand treatment options and reduce the need for mechanical ventilation — a critical goal in neonatal care.
The company said it will issue further updates as development milestones advance.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.